Literature DB >> 34595766

HPV-associated oropharyngeal cancer de-escalation strategies and trials: Past failures and future promise.

Kaveh Zakeri1, Lara Dunn2, Nancy Lee1.   

Abstract

HPV-associated oropharynx squamous cell carcinomas are radiosensitive and chemosensitive, thus, portending a favorable prognosis. Treatment de-intensification strategies aim to reduce toxicity while maintaining efficacy. Although approaches that have substituted cisplatin with cetuximab or omitted chemotherapy have not been successful, Transoral Robotic Surgery with de-intensified adjuvant therapy has been promising. Additionally, personalized approaches are taking advantage of tumor biology and utilizing tumor reduction or hypoxia on imaging as a predictive marker to successfully de-escalate radiotherapy and chemotherapy.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  HPV-associated; oropharynx cancer; treatment de-escalation

Mesh:

Year:  2021        PMID: 34595766      PMCID: PMC9387569          DOI: 10.1002/jso.26696

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   2.885


  34 in total

1.  Head and neck cancer: the importance of oxygen.

Authors:  D J Terris
Journal:  Laryngoscope       Date:  2000-05       Impact factor: 3.325

2.  Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.

Authors:  Brian O'Sullivan; Shao Hui Huang; Jie Su; Adam S Garden; Erich M Sturgis; Kristina Dahlstrom; Nancy Lee; Nadeem Riaz; Xin Pei; Shlomo A Koyfman; David Adelstein; Brian B Burkey; Jeppe Friborg; Claus A Kristensen; Anita B Gothelf; Frank Hoebers; Bernd Kremer; Ernst-Jan Speel; Daniel W Bowles; David Raben; Sana D Karam; Eugene Yu; Wei Xu
Journal:  Lancet Oncol       Date:  2016-02-27       Impact factor: 41.316

3.  Not All 30-Gy Regimens Are Equal.

Authors:  Adam S Garden
Journal:  J Clin Oncol       Date:  2019-09-26       Impact factor: 44.544

4.  Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

Authors:  Bhishamjit S Chera; Robert J Amdur; Rebecca Green; Colette Shen; Gaorav Gupta; Xianming Tan; Mary Knowles; David Fried; Neil Hayes; Jared Weiss; Juneko Grilley-Olson; Shetal Patel; Adam Zanation; Trevor Hackman; Jose Zevallos; Jeffrey Blumberg; Samip Patel; Mohit Kasibhatla; Nathan Sheets; Mark Weissler; Wendell Yarbrough; William Mendenhall
Journal:  J Clin Oncol       Date:  2019-08-14       Impact factor: 44.544

5.  Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.

Authors:  Anthony C Nichols; Julie Theurer; Eitan Prisman; Nancy Read; Eric Berthelet; Eric Tran; Kevin Fung; John R de Almeida; Andrew Bayley; David P Goldstein; Michael Hier; Khalil Sultanem; Keith Richardson; Alex Mlynarek; Suren Krishnan; Hien Le; John Yoo; S Danielle MacNeil; Eric Winquist; J Alex Hammond; Varagur Venkatesan; Sara Kuruvilla; Andrew Warner; Sylvia Mitchell; Jeff Chen; Martin Corsten; Stephanie Johnson-Obaseki; Libni Eapen; Michael Odell; Christina Parker; Bret Wehrli; Keith Kwan; David A Palma
Journal:  Lancet Oncol       Date:  2019-08-12       Impact factor: 41.316

6.  Human papillomavirus-related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor.

Authors:  Jeffrey Vainshtein; Jonathan B McHugh; Matthew E Spector; Heather M Walline; Christine M Komarck; Matthew H Stenmark; Mark E Prince; Francis P Worden; Gregory T Wolf; Carol R Bradford; Douglas B Chepeha; Thomas Carey; Avraham Eisbruch
Journal:  Head Neck       Date:  2014-04-15       Impact factor: 3.147

7.  HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.

Authors:  Thorsten Rieckmann; Silke Tribius; Tobias J Grob; Felix Meyer; Chia-Jung Busch; Cordula Petersen; Ekkehard Dikomey; Malte Kriegs
Journal:  Radiother Oncol       Date:  2013-04-17       Impact factor: 6.280

8.  A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus-Related Squamous Cell Carcinoma of the Oropharynx.

Authors:  Samuel Swisher-McClure; John N Lukens; Charu Aggarwal; Peter Ahn; Devraj Basu; Joshua M Bauml; Robert Brody; Ara Chalian; Roger B Cohen; Alireza Fotouhi-Ghiam; Geoffrey Geiger; Jared Gershowitz; Virginia Livolsi; Nandita Mitra; Kathleen Montone; Jason Newman; Eric Ojerholm; Bert O'Malley; Karthik Rajasekaran; Erik Tan; Gregory Weinstein; Alexander Lin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-11-27       Impact factor: 7.038

9.  Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).

Authors:  Robert L Ferris; Yael Flamand; Gregory S Weinstein; Shuli Li; Harry Quon; Ranee Mehra; Joaquin J Garcia; Christine H Chung; Maura L Gillison; Umamaheswar Duvvuri; Bert W O'Malley; Enver Ozer; Giovana R Thomas; Wayne M Koch; Neil D Gross; R Bryan Bell; Nabil F Saba; Miriam Lango; Eduardo Méndez; Barbara Burtness
Journal:  J Clin Oncol       Date:  2021-10-26       Impact factor: 50.717

10.  Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study.

Authors:  Danny Rischin; Madeleine King; Lizbeth Kenny; Sandro Porceddu; Christopher Wratten; Andrew Macann; James E Jackson; Mathias Bressel; Alan Herschtal; Richard Fisher; Tsien Fua; Charles Lin; Chen Liu; Brett G M Hughes; Margaret McGrath; Lachlan McDowell; June Corry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-06-04       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.